CD27/NF-kB Reporter-Jurkat Recombinant Cell Line | 79509

CD27/NF-kB Reporter-Jurkat Recombinant Cell Line | 79509 | Gentaur US, UK & Europe Disrtribition

Category: Immunotherapy/Cell Line

Application: • Screen for agonists or antagonists of CD27-CD70 signaling in a physiologically relevant cellular context • Characterize T cell-mediated immune responses of CD27 and its interaction with CD70

Background: CD27 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the T cell co-stimulatory receptors OX40, 4-1BB and herpesvirus entry mediator (HVEM). CD27 is expressed on various types of T cells, B cells and a subset of natural killer cells. It activates NF-κB and MAPK/JNK signaling upon interaction with its TNF-like ligand, CD70, which is expressed by numerous tumor cells. Adaptor proteins TRAF2 and TRAF5 can also stimulate CD27 signaling. Activation of CD27 leads to lymphoid proliferation, differentiation, apoptosis, and the induction of long-term memory. The CD27/CD70 pathway is a key target for the development of treatments for cancer and inflammatory diseases.

Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NF-kB response elements with constitutive expression of human CD27 (also known as Tumor Necrosis Factor Receptor Superfamily Member 7, TNFRSF7, and T14, Genbank Accession #BC012160)

Product Type: Cell Line

Shippement Condition: -80°C